Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.44 |
| ▸ | LIPC | P11150 | 4/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810257 | 0.82 | AAK1 (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 | |
| SCHEMBL12810048 | 0.82 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL888952 | 0.79 | AAK1 (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 | |
| SCHEMBL12810070 | 0.78 | AAK1 (0.46) | AAK1LIPG | |
| SCHEMBL14046219 | 0.77 | SMN1; SMN2 (0.34) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL888900 | 0.75 | AAK1 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 | |
| SCHEMBL890259 | 0.75 | CASR (0.51) | AAK1 | |
| SCHEMBL14046224 | 0.73 | ACACB (0.38) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL4788348 | 0.73 | DYRK1A (0.49) | AAK1 | |
| SCHEMBL888965 | 0.72 | AAK1 (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | PIK3CD 738/4885PIK3CA 537/4885PIK3CB 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.